BIOVALLEY

What BIOVALLEY does

BIOVALLEY (云南生物谷药业股份有限公司, Yunnan BioValley Pharmaceutical Co., Ltd.) is a Yunnan-based, publicly listed (Beijing Stock Exchange: 833266) Chinese pharmaceutical company founded in 1999 that specializes in the research, development, manufacture, and sale of botanical drugs derived from Dengzhanhua (灯盏花, Erigeron breviscapus) for the prevention and treatment of cardiovascular and cerebrovascular diseases. The company operates a vertically integrated value chain spanning proprietary raw material cultivation in Yunnan (which accounts for over 95% of China's Dengzhanhua cultivation area), processing via its Honghe and Mile subsidiaries (capable of handling 30 tons of fresh herbs daily and producing 5,000 tons of TCM materials annually), R&D at a nationally certified enterprise technology center and post-doctoral research workstation, and nationwide commercial distribution.

Its commercial product line consists of six Dengzhanhua-series formulations collectively marketed as the "Dengzhan Family" (灯盏家族): Dengzhan Shengmai Capsules (the only Class-A evidence-based TCM for stroke secondary prevention, a national essential medicine), Dengzhanxixin Injection (a flagship acute-care sterile aqueous injection), Dengzhanhuasu Tablets, Dengzhanhua Drop Pills, Dengzhanxixin Capsules, and Dengzhanxixin Soft Capsules. The Dengzhan family collectively represents approximately 98% of company revenue. The company holds approximately 50 core invention patents, operates GMP-compliant manufacturing with HPLC/LC-MS/NMR quality control, and has secured inclusion of its flagship products in multiple national stroke prevention and TCM clinical guidelines (2021-2023).

BIOVALLEY generates revenue primarily through one-time product sales via two channels: hospital prescriptions (managed by a Beijing-based marketing center and field sales representatives targeting secondary/tertiary hospitals) and retail pharmacy distribution of over-the-counter Dengzhanhua products. End customers include public medical institutions (hospitals), retail pharmacies, and an emerging grassroots primary care customer segment. FY2021 revenue was approximately 566 million RMB with Q1-Q3 2023 revenue at 419 million RMB representing 32.76% YoY growth. The company is pursuing expansion into India's precision medicine market via a 2026 AMTZ BioSphere MoU and deeper grassroots medical penetration domestically, while facing governance risks related to controlling shareholder judicial auction activity disclosed in 2023.

Name

BIOVALLEY

Legal name

云南生物谷药业股份有限公司

Website

https://biovalley.cn

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

251–500 employees

Short description

BIOVALLEY is a Yunnan-based Chinese pharmaceutical company that develops, manufactures, and sells six Dengzhanhua (Erigeron breviscapus) botanical drug formulations for cardiovascular and cerebrovascular disease treatment, serving public hospitals, retail pharmacies, and grassroots medical institutions nationwide with vertically integrated raw material cultivation and GMP manufacturing.

Ownership category

akta.pro rank

Product category

Traditional Chinese Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Traditional Chinese medicine
• Cardiovascular pharmaceuticals
• Botanical drug manufacturing
• Chinese patent medicines
• Pharmaceutical R&D

Headquarters

HQ city

Kunming

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations, Infrastructure

Revenue model

1. 灯盏花系列中成药销售 (Dengzhanhua series TCM product sales): Sales of six Dengzhanhua-based pharmaceutical products including Dengzhan Shengmai capsules and Dengzhanxixin injection, which together account for approximately 98% of company revenue. Products are sold through hospital prescriptions and pharmacy channels. Revenue derived from product manufacturing and direct commercial distribution.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

BIOVALLEY is a specialized high-tech pharmaceutical company that develops, manufactures, and commercializes Dengzhanhua (Erigeron breviscapus)-based traditional Chinese medicines for the prevention and treatment of cardiovascular and cerebrovascular diseases. The company offers six Dengzhanhua-series products spanning injectables, capsules, tablets, and drop pills, with its Dengzhan Shengmai Jiaonang and Dengzhanxixin Zhusheye serving as the core revenue-generating products (approximately 98% of revenue). It operates an integrated supply chain spanning Dengzhanhua cultivation, raw material processing, R&D, manufacturing, and nationwide distribution through hospital prescriptions and pharmacy channels.

Product overview

BIOVALLEY (云南生物谷药业股份有限公司) is a specialized high-tech pharmaceutical company focused on the prevention and treatment of cardiovascular and cerebrovascular diseases through Dengzhanxi (灯盏细辛, Erigeron breviscapus) based traditional Chinese medicines. The company operates a portfolio of six Dengzhanxi-series products, collectively referred to as the "Dengzhanxi Family" (灯盏家族). The core products are 灯盏生脉胶囊 (Dengzhan Shengmai Jiaonang), a stroke secondary prevention capsule and national essential medicine, and 灯盏细辛注射液 (Dengzhanxixin Zhusheye), an injectable solution for acute ischemic conditions. Supporting products include 灯盏花素片 (Dengzhanhuasu Pian), a tablet for post-stroke recovery; 灯盏花滴丸 (Dengzhanhua Diwan), a drop pill for cerebrovascular recovery; 灯盏细辛胶囊 (Dengzhanxixin Jiaonang), a capsule for blood circulation; and 灯盏细辛软胶囊 (Dengzhanxixin Ruanjiaonang), a soft capsule for the same therapeutic indication. The company operates as a specialized pharmaceutical manufacturer integrating research, development, production, and sales of plant-based medicines.

Differentiator

Problem solved

Functional benefit

Brands

• 灯盏家族: Product family including 灯盏生脉胶囊, 灯盏细辛注射液, 灯盏花素片, 灯盏花滴丸, 灯盏细辛胶囊, 灯盏细辛软胶囊

Products and services

• Dengzhan Shengmai Jiaonang (灯盏生脉胶囊) A hard capsule formulation based on Dengzhanhua, indicated for the recovery phase treatment and secondary prevention of ischemic cardiovascular and cerebrovascular diseases, including stroke sequelae, coronary heart disease, and angina pectoris. Targeted at hospitals and healthcare institutions for prescription-based use.
• Dengzhanxixin Zhusheye (灯盏细辛注射液) A sterile aqueous injection extracted from Erigeron breviscapus, used for blood circulation promotion and pain relief in acute ischemic cerebrovascular conditions, ischemic stroke, and coronary heart disease. Contains defined active ingredients with full-process HPLC quality control. Targeted at hospital prescription use for acute treatment.
• Dengzhanhuasu Pian (灯盏花素片) A simple flavonoid (scutellarin) tablet primarily used for the treatment of post-stroke sequelae and coronary heart disease. Available as an oral formulation listed in National Basic Medical Insurance Catalog 2024 Category A.
• Dengzhanhua Diwan (灯盏花滴丸) A drop pill formulation processed from Dengzhanxi, used for cerebrovascular accident recovery and coronary heart disease with angina symptoms. Suitable for chronic disease long-term management. Listed in National Basic Medical Insurance Catalog.
• Dengzhanxixin Jiaonang (灯盏细辛胶囊) A capsule formulation of Dengzhanxi used for blood circulation promotion in stroke rehabilitation and coronary heart disease with chest pain symptoms. Contents are black-brown granules. Each capsule contains 0.18g. Approval number: 国药准字Z53021671.
• Dengzhanxixin Ruanjiaonang (灯盏细辛软胶囊) A soft capsule formulation of Dengzhanxi containing dark-brown viscous liquid, used for blood circulation promotion in stroke and coronary heart disease. Approval number: 国药准字Z20070058.

Quantifiable outcome

• 灯盏生脉胶囊在常规二级预防策略基础上联用可降低缺血性卒中患者近30%的一年期复发率且不增加出血风险
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Chinese Biopharmaceutical Association (CBA) China BranchcoreStrategic or Co-development Partner · 8 May 2026BioValley co-hosted the 2026 CBA-China Annual Conference held May 8-10, 2026 in Wuxi, Jiangsu Province, China. The three-day event brought together hundreds of global biopharmaceutical professionals to discuss supply chain collaboration, AI technologies in life sciences, and digital healthcare opportunities.
• Andhra Pradesh MedTech Zone (AMTZ), IndiaminorStrategic or Co-development Partner · 2 March 2026BioValley partnered with 4baseCare and Define Bio Pvt Ltd to sign an MoU establishing a Centre of Excellence named BioSphere at AMTZ in Visakhapatnam, India, dedicated to genomics and next-generation sequencing for precision medicine.
• 广州中医药大学 (Guangzhou University of Chinese Medicine)coreStrategic or Co-development Partner · 1 January 2022Guangzhou University of Chinese Medicine led a research project on ischemic stroke prevention, with BioValley as a co-participant. The 'Ischemic Stroke Integrated TCM-WM Secondary Prevention Protocol: Evidence-Based Evaluation Research and Application Promotion' project received the National Ministry of Education Science and Technology Progress Award Second Prize in 2023.
• 海军军医大学附属上海长征医院 (Naval Medical University Shanghai Changzheng Hospital)coreStrategic or Co-development Partner · 1 April 2019Professor Qu Lefeng's team at Shanghai Changzheng Hospital Vascular Surgery Department conducted a randomized controlled study comparing Dengzhan Shengmai capsules with aspirin for carotid atherosclerosis treatment, published in Phytomedicine (IF: 6.656).
• Duke University (杜克大学)coreStrategic or Co-development Partner · 30 November 2018BioValley collaborates with Duke University on pharmaceutical research and development, including产学研合作 (industry-university-research cooperation) for product innovation and clinical evidence development.
• 中国中医科学院中药研究所 (Chinese Academy of Chinese Medical Sciences - Institute of Chinese Materia Medica)coreStrategic or Co-development Partner · 30 November 2018Academic research partnership for traditional Chinese medicine pharmacology and clinical research collaboration.
• 中国医学科学院药物研究所 (Chinese Academy of Medical Sciences - Institute of Materia Medica)coreStrategic or Co-development Partner · 30 November 2018Academic research partnership for drug development and pharmacological research collaboration.
• 上海中医药大学 (Shanghai University of Traditional Chinese Medicine)coreStrategic or Co-development Partner · 30 November 2018Academic research partnership for TCM clinical research, product development, and talent cultivation.

Scale indicators15 records

Recent moves15 records

Expansion highlights6 records

Broad incumbents

• Shanghai Pharmaceuticals Holding: Major listed Chinese pharmaceutical conglomerate combining branded drug manufacturing (including TCM) with large-scale distribution. Its TCM manufacturing arm operates in overlapping therapeutic categories, and its distribution business reaches the same hospitals where BIOVALLEY's field sales team promotes its Dengzhanxia products.
• Pien Tze Huang (Zhangzhou Pien Tze Huang Pharmaceutical): Fujian-based listed TCM manufacturer known for premium branded TCM products with national retail and growing hospital presence. While its flagship indications differ, its business model — branded, IP-protected, evidence-promoted TCM with strong trademark equity — parallels BIOVALLEY's positioning strategy.
• China Resources Sanjiu Medical & Pharmaceutical: Large state-backed TCM and OTC pharmaceutical manufacturer with national distribution and hospital coverage. It overlaps with BIOVALLEY through hospital-prescribed branded TCM products and serves overlapping physician customers, though its portfolio is significantly broader and less specialized in cardiovascular botanical drugs.

Direct peers

• Zhejiang Conba Pharmaceutical: Zhejiang-based TCM manufacturer with significant cardiovascular and cerebrovascular product lines and national hospital distribution. Comparable to BIOVALLEY as a mid-sized branded TCM company targeting similar prescription specialists with botanical cardiovascular preparations.
• Livzon Pharmaceutical Group: Chinese pharmaceutical manufacturer combining TCM preparations (including cardiovascular and cerebrovascular indications) with chemical drugs. Comparable to BIOVALLEY in its dual TCM/biologics orientation, listed status, and strategy of using clinical evidence to drive hospital prescription adoption.
• China Traditional Chinese Medicine Holdings: Hong Kong-listed core subsidiary of Sinopharm focused exclusively on TCM manufacturing, including botanical drug products targeting cardiovascular indications. It competes directly with BIOVALLEY for national-level clinical guideline inclusions and is a useful scale benchmark within Chinese TCM.
• China Shineway Pharmaceutical Holdings: Hong Kong-listed Chinese TCM manufacturer known for its 'Shenmai' and 'Qing Kai Ling' injectable and oral product families. Its product positioning around cardiovascular and critical-care injections closely mirrors BIOVALLEY's Dengzhanxia injectable franchise and competes for similar hospital prescription channels.
• Tasly Pharmaceutical Group: Tianjin-based Chinese TCM pharmaceutical company that, like BIOVALLEY, focuses on cardiovascular and cerebrovascular indications using botanical active ingredients. Both companies compete in the Chinese branded TCM cardiovascular space, share hospital-channel promotion models, and invest heavily in clinical-evidence generation for inclusion in national guidelines.
• Yiling Pharmaceutical (Yiling 石家庄以岭药业): Chinese TCM pharmaceutical company built around academic-evidence-driven cardiovascular and metabolic franchises. It is a particularly close comparable to BIOVALLEY given its emphasis on guideline inclusion (e.g., TCM products for stroke/cardiovascular secondary prevention) and academic promotion through hospital detailing.

Regional players

• Yunnan Baiyao Group: Yunnan-headquartered flagship TCM company with broad botanical drug portfolio, also publicly listed and based in the same province as BIOVALLEY. It is the dominant Yunnan TCM brand, providing regional context for BIOVALLEY's smaller, more specialized Dengzhanhua franchise and competing for the same institutional and consumer mindshare.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOVALLEY